ATLANTA, Oct. 31, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that after the market close on Monday, November 11, 2013, it will release its third quarter fiscal year 2013 financial results. An investor conference call will follow on the same day at 4:30 p.m. ET to discuss those results and provide an update regarding its upcoming meeting with the U.S. Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee in January 2014 to discuss the Company's New Drug Application for ILUVIEN.
The conference call will be hosted by Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com.
A replay of the conference call will be available beginning November 11, 2013 at 7:30 p.m. ET and ending on November 17, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 92324341. A replay of the webcast will be available on the corporate website for one week, through November 17, 2013.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceutica
|SOURCE Alimera Sciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved